Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain

Virology Journal

Vincent Soriano^1,12  Carmen de Mendoza^1,12  Raul Ortíz de Lejarazu⁷  Cesar Gomez²  Matilde Trigo³  Carmen Rodríguez⁴  Goitzane Marcaida⁵  Lourdes Roc^1,10  Jose Manuel Ramos⁶  Juan García^1,13  Alvaro Torres^1,15  Manuel Rodríguez¹  Enrique Calderón^1,14  Araceli Hernandez^1,11  Jose M Eiros⁷  Patricia Parra^1,12  Rafael Benito⁸  Estrella Caballero^1,16  Antonio Aguilera⁹  Ana Treviño^1,12 

[1] Service of Microbiology, Hospital Universitario Puerta del Mar, Cádiz, Spain;Service of Microbiology, Complejo Hospitalario Virgen de la Salud, Toledo, Spain;Service of Microbiology, Complejo Hospitalario, Pontevedra, Spain;Centro Sanitario Sandoval, Madrid, Spain;Center of Biomedical Diagnostic, Hospital General Universitario, Valencia, Spain;Infectious Disease Unit, Hospital General, Elche, Spain;Service of Microbiology, Hospital Clínico Universitario, Valladolid, Spain;Service of Microbiology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain;Service of Microbiology, Hospital Conxo, Santiago de Compostela, Spain;Service of Microbiology, Hospital Miguel Servet, Zaragoza, Spain;Service of Microbiology, Hospital Universitario Insular, Las Palmas de Gran Canaria, Spain;Infectious Diseases Department, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain;Service of Microbiology, Hospital Cristal-Piñor, Orense, Spain;CIBER in Public Health and Epidemiology, Hospital Universitario Virgen del Rocío, Seville, Spain;Service of Microbiology Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain;Service of Microbiology, Hospital Vall d'Hebron, Barcelona, Spain

关键词: HTLV-4;    HTLV-3;    Epidemiology;    Seroprevalence;    Spain;    HTLV;   

Others  :  1154838
DOI  :  10.1186/1743-422X-9-71

 received in 2011-10-17, accepted in 2012-03-23,  发布年份 2012

【 摘 要 】

Background

Although most HTLV infections in Spain have been found in native intravenous drug users carrying HTLV-2, the large immigration flows from Latin America and Sub-Saharan Africa in recent years may have changed the prevalence and distribution of HTLV-1 and HTLV-2 infections, and hypothetically open the opportunity for introducing HTLV-3 or HTLV-4 in Spain. To assess the current seroprevalence of HTLV infection in Spain a national multicenter, cross-sectional, study was conducted in June 2009.

Results

A total of 6,460 consecutive outpatients attending 16 hospitals were examined. Overall, 12% were immigrants, and their main origin was Latin America (4.9%), Africa (3.6%) and other European countries (2.8%). Nine individuals were seroreactive for HTLV antibodies (overall prevalence, 0.14%). Evidence of HTLV-1 infection was confirmed by Western blot in 4 subjects (prevalence 0.06%) while HTLV-2 infection was found in 5 (prevalence 0.08%). Infection with HTLV types 1, 2, 3 and 4 was discarded by Western blot and specific PCR assays in another two specimens initially reactive in the enzyme immunoassay. All but one HTLV-1 cases were Latin-Americans while all persons with HTLV-2 infection were native Spaniards.

Conclusions

The overall prevalence of HTLV infections in Spain remains low, with no evidence of HTLV-3 or HTLV-4 infections so far.

【 授权许可】

   
2012 Treviño et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Poiesz B, Ruscetti F, Gazdar A, Bunn P, Minna J, Gallo R: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:7415-7419.
• [2]Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de Thé G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
• [3]Toro C, Blanco F, García-Gascó P, Sheldon J, Benito JM, Rallón NI, Soriano V: HTLV type 1-associated myelopathy/tropical spastic paraparesis in an HIV-positive patient coinfected with HTLV type 2 following initiation of antiretroviral therapy. Clin Infect Dis 2007, 45:e118-e120.
• [4]Roucoux D, Murphy E: The epidemiology and disease outcomes of human T lymphotropic virus type II. AIDS Rev 2004, 6:144-154.
• [5]Calattini S, Chevalier SA, Duprez R, Bassot S, Froment A, Mahieux R, Gessain A: Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retrovirology 2005, 2:30. BioMed Central Full Text
• [6]Wolfe ND, Heneine W, Carr JK, Garcia AD, Shanmugam V, Tamoufe U, Torimiro JN, Prosser AT, Lebreton M, Mpoudi-Ngole E, McCutchan FE, Birx DL, Folks TM, Burke DS, Switzer WM: Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci USA 2005, 102:7994-7999.
• [7]Calattini S, Betsem E, Bassot S, Chevalier S, Mahieux R, Froment A, Gessain A: New strain of human T lymphotropic virus (HTLV) type 3 in a Pygmy from Cameroon with peculiar HTLV serologic results. J Infect Dis 2009, 199:561-564.
• [8]Bagossi P, Bander P, Bozóki B, Tozser J: Discovery and significance of new human T-lymphotropic viruses: HTLV-3 and HTLV-4. Expert Rev Anti Infect Ther 2009, 7:1235-1249.
• [9]Proietti F, Carneiro-Proietti A, Catalan-Soares B, Murphy E: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
• [10]Verdonck K, Gonzalez E, Van Dooren S, Vandamme A, Vanham G, Gotuzzo E: Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007, 7:266-281.
• [11]Treviño A, Aguilera A, Caballero E, Toro C, Eiros JM, Ortiz-de-Lejarazu R, Rodríguez-Calviño JJ, Tuset C, Gómez-Hernando C, Rodríguez-Iglesias M, Ramos JM, Rodríguez-Díaz JC, Benito R, Trigo M, García-Campello M, Calderón E, Garcia J, Rodríguez C, Soriano V: Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain. AIDS Res Hum Retroviruses 2009, 25:551-554.
• [12]Toro C, Jiménez V, Rodríguez C, Del Romero J, Rodés B, Holguín A, Alvarez P, García-Campello M, Gómez-Hernando C, Guelar A, Sheldon J, de Mendoza C, Simón A, Soriano V: Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. J Med Virol 2006, 78:1599-1608.
• [13]Treviño A, Soriano V, Grupo Español para el Estudio del VIH-2 y HTLV: Current situation of HIV type 2 and HTLV in Spain. Enferm Infecc Microbiol Clin 2010, 28:442-445.
• [14]Toro C, Aguilera A, Caballero E, Tuset C, Alvarez P, García-Campello M, Rodríguez-Iglesias M, de Lejarazu RO, Eiros J, Rodriguez C, del Romero J, Benito R, Calderón E, Santana O, Amor A, Gómez-Hernando C, García J, Soriano V: Hospital-based surveillance for HTLV-1/2 infections in Spain. AIDS Res Hum Retroviruses 2007, 23:1075-1077.
• [15]Treviño A, García J, de Mendoza C, Benito R, Aguilera A, Ortíz-de-Lejarazu R, Ramos JM, Trigo M, Eirós JM, Rodríguez-Iglesias M, Torres A, Calderón E, Hernandez A, Gomez C, Marcaida G, Soriano V, HTLV Spanish Study Group: Prevalence of HTLV-1/2 infections in Spain: a cross-sectional hospital-based survey. AIDS Res Hum Retroviruses 2010, 26:861-864.
• [16]Instituto Nacional de Estadística: Revisión del padron municipal 2009. 2010. Available in: http://www.ine.es webcite [1/8/2010]
• [17]Toro C, Rodés B, Bassani S, Jiménez V, Tuset C, Brugal MT, de la Fuente L, Soriano V, HTLV Spanish Study Group: Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. J Clin Virol 2005, 33:65-70.
• [18]The HTLV European Research Network: Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 14:68-77.
• [19]Pérez-Cachafeiro S, del Amo J, Iribarren JA, Salavert-Lleti M, Gutiérrez F, Moreno A, Labarga P, Pineda JA, Vidal F, Berenguer J, Moreno S, Cohorts of the Spanish AIDS Research Network (CoRIS and CoRIS-MD): Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis 2009, 48:1467-1470.
• [20]Perzova R, Benz P, Abbott L, Welch C, Thomas A, El-Ghoul R, Sanghi S, Nara P, Glaser J, Siegal FP, Dosik H, Poiesz BJ: Short communication: no evidence of HTLV-3 and HTLV-4 infection in New York State subjects at risk for retroviral infection. AIDS Res Hum Retroviruses 2010, 26:1229-1231.
• [21]Mahieux R, Gessain A: The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris) 2009, 57:161-166.
• [22]Switzer WM, Hewlett I, Aaron L, Wolfe ND, Burke DS, Heneine W: Serologic testing for human T-lymphotropic virus-3 and -4. Transfusion 2006, 46:1647-1648.
• [23]Andersson S, Gessain A, Taylor G: Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus (HTLV) types I and II. Virus Res 2001, 78:101-106.
• [24]Toro C, Rodés B, Poveda E, Soriano V: Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 2003, 75:102-104.
• [25]Duong YT, Jia H, Lust JA, Garcia AD, Tiffany AJ, Heneine W, Switzer WM: Short communication: absence of evidence of HTLV-3 and HTLV-4 in patients with large granular lymphocyte (LGL) leukemia. AIDS Res Hum Retroviruses 2008, 24:1503-1505.